Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial).

Fiche publication

Date publication

juillet 2023

Journal

Neuro-oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERNIER-CHASTAGNER Valérie , Pr NOEL Georges , Pr TRUC Gilles

Tous les auteurs :
Laprie A, Noel G, Chaltiel L, Truc G, Sunyach MP, Charissoux M, Magne N, Auberdiac P, Biau J, Ken S, Tensaouti F, Khalifa J, Sidibe I, Roux FE, Vieillevigne L, Catalaa I, Boetto S, Emmanuelle UC, Supiot S, Bernier V, Filleron T, Mounier M, Poublanc M, Olivier P, Delord JP, Cohen-Jonathan-Moyal E

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37417948

Résumé

Glioblastoma (GBM) systematically recurs after a standard 60 Gy radio-chemotherapy regimen. Since Magnetic Resonance Spectroscopic Imaging (MRSI) has been shown to predict the site of relapse, we analyzed the effect of MRSI-guided dose escalation on overall survival (OS) of patients with newly diagnosed GBM.